Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis.

Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production of functional cystinosin proteins. Patients experience an abnormal build-up of cysteine that can damage organs, including the kidneys.

ELX-02 is a small molecule drug candidate designed to restore production of cystinosin and preserve renal function.

Dr. Paul Goodyer, the study’s principal investigator, said that ELX-02 has “exhibited positive results in cellular and animal models with dose-dependent reductions in white blood cell cystine levels, a biomarker used to monitor cysteamine therapy and to predict clinical benefit.”

Six patients will be enrolled in the trial and receive ELX-02 for four weeks at three escalating dose levels. Eloxx plans to report topline data from the trial early in the fourth quarter of 2019.


Sign up to our weekly BioTuesdays newsletter.